

Elad Jacoby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7856737/publications.pdf>

Version: 2024-02-01

66
papers

3,457
citations

361413

20
h-index

182427

51
g-index

67
all docs

67
docs citations

67
times ranked

5172
citing authors

#	ARTICLE	IF	CITATIONS
1	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	9.4	997
2	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nature Communications</i> , 2016, 7, 12320.	12.8	325
3	Early and late hematologic toxicity following CD19 CAR-T cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1643-1650.	2.4	254
4	MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. <i>Oncotarget</i> , 2013, 4, 665-676.	1.8	181
5	MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. <i>Journal of Clinical Investigation</i> , 2013, 123, 2703-2718.	8.2	149
6	TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	136
7	Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 1347.	4.8	135
8	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
9	MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor. <i>PLoS ONE</i> , 2013, 8, e54652.	2.5	94
10	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1485-1492.	4.1	93
11	Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal CVHD. <i>Blood</i> , 2016, 127, 1361-1370.	1.4	87
12	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
13	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
14	Challenges and opportunities of allogeneic donor-derived CAR T cells. <i>Current Opinion in Hematology</i> , 2015, 22, 509-515.	2.5	81
15	Updates on CAR T cell therapy in B cell malignancies. <i>Immunological Reviews</i> , 2019, 290, 39-59.	6.0	61
16	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
17	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37
18	The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 810-814.	2.4	33

#	ARTICLE	IF	CITATIONS
19	Murine Models of Acute Leukemia: Important Tools in Current Pediatric Leukemia Research. <i>Frontiers in Oncology</i> , 2014, 4, 95.	2.8	31
20	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.	6.3	29
21	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	7.2	27
22	CAR T cells induce a complete response in refractory Burkitt Lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1583-1585.	2.4	25
23	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 17-22.	1.8	24
24	Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. , 2021, 9, e001743.		23
25	Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27898.	1.5	22
26	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. <i>Leukemia and Lymphoma</i> , 2021, 62, 1692-1701.	1.3	22
27	Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways. <i>Blood Advances</i> , 2017, 1, 1749-1759.	5.2	19
28	Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102769.	1.0	19
29	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1134-1143.	2.4	17
30	Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade Glioma. <i>World Neurosurgery</i> , 2019, 130, e324-e332.	1.3	15
31	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. <i>Clinical Hematology International</i> , 2019, 1, 79.	1.7	15
32	Mitochondrial augmentation of CD34+ cells from healthy donors and patients with mitochondrial DNA disorders confers functional benefit. <i>Npj Regenerative Medicine</i> , 2021, 6, 58.	5.2	15
33	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 251-257.	1.2	14
34	Comparison of two cytoreductive regimens for TBI-based haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI-based regimen. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26839.	1.5	12
35	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. <i>Leukemia</i> , 2020, 34, 1939-1942.	7.2	12
36	Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. <i>Blood</i> , 2019, 134, 3234-3234.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Carina Angle Measurements for Diagnosis of Patent Ductus Arteriosus in Preterm Infants. <i>Neonatology</i> , 2011, 99, 224-230.	2.0	10
38	Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 475-481.	2.5	10
39	The Effect of Prolonged Physical Activity Performed during Extreme Caloric Deprivation on Cardiac Function. <i>PLoS ONE</i> , 2012, 7, e31266.	2.5	9
40	Related to testes-specific, vespid and pathogenesis protein-1 is regulated by methylation in glioblastoma. <i>Oncology Letters</i> , 2014, 7, 1209-1212.	1.8	9
41	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. <i>Cells</i> , 2022, 11, 1140.	4.1	8
42	First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome. <i>Blood</i> , 2018, 132, 1024-1024.	1.4	7
43	Haploidentical hematopoietic stem cell transplantation with \pm TCR+/CD19+ depletion in pediatric patients with malignant and non-malignant disorders. <i>Bone Marrow Transplantation</i> , 2019, 54, 694-697.	2.4	6
44	Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. <i>Bone Marrow Transplantation</i> , 2021, 56, 2248-2258.	2.4	6
45	CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells. <i>Blood</i> , 2015, 126, 100-100.	1.4	6
46	Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR. <i>Blood</i> , 2015, 126, 2524-2524.	1.4	6
47	Improved transplant outcomes with myeloablative conditioning for hemophagocytic lymphohistiocytosis in HLA-matched and mismatched donors: a national multicenter retrospective study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2088-2096.	2.4	5
48	Neonatal Hyperpigmentation: Diagnosis of Familial Glucocorticoid Deficiency with a Novel Mutation in the Melanocortin-2 Receptor Gene. <i>Pediatric Dermatology</i> , 2014, 31, e13-7.	0.9	3
49	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3824-3824.	1.4	3
50	Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement. <i>Blood</i> , 2020, 136, 1-1.	1.4	2
51	Donor assessment and follow-up: not a minor issue. <i>Bone Marrow Transplantation</i> , 2019, 54, 1728-1729.	2.4	1
52	Senescent/Exhausted Phenotype of CAR T Cells and Induction of Immunoregulatory Environment Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S314-S315.	2.0	1
53	Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a Bridge to Immunotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.6	1
54	CRLF2 /Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells. <i>Blood</i> , 2015, 126, 1432-1432.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. <i>Blood</i> , 2021, 138, 910-910.	1.4	1
56	Adult Acute Lymphoblastic Leukaemia. , 2022, , 61-66.		1
57	Genetically Engineered T Cell Therapies and Immune System Engagers for Graft-Versus-Host Disease and Graft Versus Leukemia. , 2019, , 127-140.		0
58	CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer. , 2020, , 199-208.		0
59	CAR T cells for the long run in aggressive B-cell lymphoma. <i>Lancet Oncology</i> , The, 2021, 22, 1347-1348.	10.7	0
60	Anterior chamber infiltration of CAR T-cells. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 24, 101223.	0.7	0
61	41BBL-Based Activation and Expansion of Autologous Natural Killer Cells Results in Enhanced Activity Against Leukemia Including ALL. <i>Blood</i> , 2014, 124, 2293-2293.	1.4	0
62	CD19 CAR T Cells Maintain Efficacy in the Allogeneic Environment but Mediate Acute Graft-Versus-Host-Disease Only in the Presence CD19+ Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1115-1115.	1.4	0
63	Presence of Endogenous TCR Antigen in Vivo Attenuates Efficacy of Anti-CD19 Targeted CAR T Cell Therapy. <i>Blood</i> , 2014, 124, 3721-3721.	1.4	0
64	<i>In Vitro</i> Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
65	The Phenotypic, Transcriptional and Functional Properties of CAR T Cells Products May Predict Response of Patients with B Cell Lymphoid Malignancies Treated with CD19 CAR-T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S166.	1.2	0
66	Durable Remissions of Refractory Lymphoma in Patients with Underlying Immunodeficiencies Treated with Allogeneic HSCT. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S414.	1.2	0